Company intelligence / Profile preview
Saol Therapeutics
Roswell, Georgia, United Statessaolrx.com ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
Saol Therapeutics has achieved major clinical milestones with its lead asset SL1009, an oral sodium dichloroacetate therapy with a proprietary genetic test companion diagnostic targeting the rare pediatric mitochondrial disease PDCD. The NDA was accepted by the FDA with Priority Review and a decision expected August 2025. Another key program, SL1002—a novel chemoneurolytic injection using proprietary CYCLOPHLEX™ technology—has shown positive Phase II results in limb spasticity and chronic knee pain due to osteoarthritis. Both programs have demonstrated favorable safety profiles and significant efficacy endpoints.
- Therapeutic areas
- NeurologyMetabolic DisordersRheumatology
- Modalities
- Small molecules (e.g., Sodium Dichloroacetate)Chemoneurolytic injectionsCompanion diagnostics/genetic tests
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
Request access →03
Partnerships
Collaboration with Medosome Biotec on the development of the genetic test companion diagnostic for DCA/SL1009.
Beyond the preview
Go deeper on Saol Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Saol Therapeutics.